<p>在过去的 7 天里，美国市场下跌了 2.5%，但在过去一年中上涨了 23%，预计未来几年收益将以每年 17% 的速度增长。在这种波动的表现和预期增长的背景下，拥有高内部持股的股票可能会很有吸引力，因为它们通常表明公司运营最亲近的人对公司及其潜在的可观收益增长的信心。</p>
<h3>美国高内部持股的十大成长公司</h3>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名称</strong></td>
<td><strong>内部持股</strong></td>
<td><strong>收益增长</strong></td>
</tr>
<tr>
<td>Uxin (UXIN)</td>
<td>34.3%</td>
<td>74.1%</td>
</tr>
<tr>
<td>Upstart Holdings (UPST)</td>
<td>14.1%</td>
<td>57.3%</td>
</tr>
<tr>
<td>On Holding (ONON)</td>
<td>26%</td>
<td>23.1%</td>
</tr>
<tr>
<td>KVH Industries (KVHI)</td>
<td>16.3%</td>
<td>146.1%</td>
</tr>
<tr>
<td>Karman Holdings (KRMN)</td>
<td>15.6%</td>
<td>52.6%</td>
</tr>
<tr>
<td>Duos Technologies Group (DUOT)</td>
<td>11.2%</td>
<td>158.4%</td>
</tr>
<tr>
<td>Corcept Therapeutics (CORT)</td>
<td>11.7%</td>
<td>48.9%</td>
</tr>
<tr>
<td>Astera Labs (ALAB)</td>
<td>10.3%</td>
<td>29.3%</td>
</tr>
<tr>
<td>AppLovin (APP)</td>
<td>27.4%</td>
<td>21.7%</td>
</tr>
<tr>
<td>Abeona Therapeutics (ABEO)</td>
<td>16.7%</td>
<td>32.9%</td>
</tr>
</tbody>
</table>
<p>点击此处查看我们高内部持股的快速成长美国公司筛选器中的 176 只股票的完整列表。</p>
<p>在这里，我们重点介绍我们独家筛选器中的几只最爱。</p>
<h2>ImmunityBio (IBRX)</h2>
<p><strong>Simply Wall St 成长评级：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> ImmunityBio, Inc.是一家生物技术公司，致力于开发和商业化先进的免疫疗法，旨在增强免疫系统对癌症和传染病的反应，市值约为 72.5 亿美元。</p>
<p><strong>运营：</strong> 该公司从其专注于开发下一代疗法的部门产生了 1.4098 亿美元的收入。</p>
<p><strong>内部持股：</strong> 28.2%</p>
<p><strong>收益增长预测：</strong> 每年 64.1%。</p>
<p>ImmunityBio 是一家以增长为导向的公司，内部持股显著，正在推进其针对 BCG 无反应非肌肉侵袭性膀胱癌的 ANKTIVA 治疗。最近 FDA 接受其补充生物制剂许可证申请，可能会扩大 ANKTIVA 的适应症。尽管预计年收入增长 47.8%，ImmunityBio 面临财务挑战，现金流不足一年，且最近出现股东稀释。分析师一致认为股票价格有上涨潜力，尽管该公司目前的交易价格远低于估计的公允价值。</p>
<ul>
<li>解锁我们对 ImmunityBio 股票分析的全面见解，详见本成长报告。</li>
<li>在审查我们最新的估值报告后，ImmunityBio 的股价可能过于悲观。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/b2d6e0fd-dc1f-4014-8f92-60363368b53b/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1642" height="1048" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/b2d6e0fd-dc1f-4014-8f92-60363368b53b/chart/earnings-and-revenue-growth"/></p>
<p>截至 2026 年 6 月的 IBRX 收益和收入增长</p>
<h2>理想汽车 (LI)</h2>
<p><strong>Simply Wall St 成长评级：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> 理想汽车在中华人民共和国的能源汽车市场运营，市值约为 144.8 亿美元。</p>
<p><strong>运营：</strong> 理想汽车主要通过其汽车制造部门产生收入，总计为 1093.7 亿人民币。</p>
<p><strong>内部持股：</strong> 33%</p>
<p><strong>收益增长预测：</strong> 每年 61.6%。</p>
<p>理想汽车以高内部持股为特征，在挑战中寻求增长。该公司预计年收入增长 13%，超过美国市场。然而，最近的收益显示 2026 年第一季度净亏损 22.9 亿人民币，尽管车辆交付量已超过 170 万辆。理想汽车的战略举措包括 10 亿美元的股票回购和推出新车型如理想 L9，以增强其在竞争激烈的电动车市场中的地位。</p>
<ul>
<li>在我们的收益增长报告中更深入地了解理想汽车的潜力。</li>
<li>我们精心准备的理想汽车估值报告表明，其股价可能过高。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/9eb69e11-e6b7-42a1-afa3-9f2354e8ac7f/chart/ownership-breakdown?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1642" height="540" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/9eb69e11-e6b7-42a1-afa3-9f2354e8ac7f/chart/ownership-breakdown"/></p>
<p>截至 2026 年 6 月的 LI 持股结构</p>
<h2>Ethos Technologies (LIFE)</h2>
<p><strong>Simply Wall St 成长评级：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> Ethos Technologies Inc.在美国作为保险政策的第三方管理者运营，市值约为 10.6 亿美元。</p>
<p><strong>运营：</strong> 该公司主要通过其保险经纪服务产生收入，总计为 4.8582 亿美元。</p>
<p><strong>内部持股：</strong> 22%</p>
<p><strong>收益增长预测：</strong> 每年 94.5%。</p>
<p>Ethos Technologies 拥有显著的内部持股，通过战略合作和技术进步扩展其数字人寿保险产品。与 Liberty Mutual 和 Banner Life Insurance 的近期合作增强了 Ethos 的市场覆盖和产品组合。尽管 2026 年第一季度净亏损为 1.6639 亿美元，收入从去年激增至 1.931 亿美元。推出 ChatGPT 应用程序标志着他们在不断发展的保险领域中对消费者参与的创新方法，尽管最近注意到内部人士的卖出。</p>
<ul>
<li>通过我们的全面分析师估计报告深入了解 Ethos Technologies。</li>
<li>在审查我们最新的估值报告后，Ethos Technologies 的股价可能过于乐观。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/fbc02edd-aafc-4f38-aa18-ae0098f75905/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1642" height="1048" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/fbc02edd-aafc-4f38-aa18-ae0098f75905/chart/earnings-and-revenue-growth"/></p>
<p>截至 2026 年 6 月的 LIFE 收益和收入增长</p>
<h2>抓住机会</h2>
<ul>
<li>点击此链接深入了解我们高内部持股的快速成长美国公司筛选器中的 176 家公司。</li>
<li>对其他选择感到好奇？这项技术可能会取代计算机：发现 30 只股票正在努力使量子计算成为现实。</li>
</ul>
<p><em>这篇来自 Simply Wall St 的文章是一般性的。<strong>我们提供的评论基于历史数据和分析师预测，仅使用无偏见的方法，我们的文章并不旨在提供财务建议。</strong> 它不构成买卖任何股票的推荐，也未考虑您的目标或财务状况。我们的目标是为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。该分析仅考虑内部人士直接持有的股票，不包括通过其他工具（如公司和/或信托实体）间接持有的股票。所有预测的收入和收益增长率均以年化（每年）增长率的形式表示，时间范围为 1-3 年。</em></p>
<h3>估值是复杂的，但我们在这里为您简化它。</h3>
<p>通过我们的详细分析，发现 Ethos Technologies 是否被低估或高估，分析内容包括 <strong>公允价值估算、潜在风险、股息、内部交易及其财务状况。</strong></p>
<p>获取免费分析</p>

LIFE

IBRX

<p>这篇文章强调了美国一些高管持股比例较高的成长型公司，如 ImmunityBio、理想汽车和 Ethos Technologies，指出它们在盈利增长方面的潜力。文章概述了这些公司的运营情况、高管持股和财务预测，同时提醒读者，内容是基于历史数据的一般分析，并非财务建议</p>

<p>Over the last 7 days, the United States market has dropped by 2.5%, yet it has risen by 23% over the past year, with earnings expected to grow by 17% annually in the coming years. In this context of fluctuating performance and anticipated growth, stocks with high insider ownership can be appealing as they often signal confidence from those closest to the company's operations and potential for substantial earnings growth.</p>
<div class="lb-trans"><p>在过去的 7 天里，美国市场下跌了 2.5%，但在过去一年中上涨了 23%，预计未来几年收益将以每年 17% 的速度增长。在这种波动的表现和预期增长的背景下，拥有高内部持股的股票可能会很有吸引力，因为它们通常表明公司运营最亲近的人对公司及其潜在的可观收益增长的信心。</p>
</div><h3>Top 10 Growth Companies With High Insider Ownership In The United States</h3>
<div class="lb-trans"><h3>美国高内部持股的十大成长公司</h3>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Name</strong></td>
<td><strong>Insider Ownership</strong></td>
<td><strong>Earnings Growth</strong></td>
</tr>
<tr>
<td>Uxin (UXIN)</td>
<td>34.3%</td>
<td>74.1%</td>
</tr>
<tr>
<td>Upstart Holdings (UPST)</td>
<td>14.1%</td>
<td>57.3%</td>
</tr>
<tr>
<td>On Holding (ONON)</td>
<td>26%</td>
<td>23.1%</td>
</tr>
<tr>
<td>KVH Industries (KVHI)</td>
<td>16.3%</td>
<td>146.1%</td>
</tr>
<tr>
<td>Karman Holdings (KRMN)</td>
<td>15.6%</td>
<td>52.6%</td>
</tr>
<tr>
<td>Duos Technologies Group (DUOT)</td>
<td>11.2%</td>
<td>158.4%</td>
</tr>
<tr>
<td>Corcept Therapeutics (CORT)</td>
<td>11.7%</td>
<td>48.9%</td>
</tr>
<tr>
<td>Astera Labs (ALAB)</td>
<td>10.3%</td>
<td>29.3%</td>
</tr>
<tr>
<td>AppLovin (APP)</td>
<td>27.4%</td>
<td>21.7%</td>
</tr>
<tr>
<td>Abeona Therapeutics (ABEO)</td>
<td>16.7%</td>
<td>32.9%</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名称</strong></td>
<td><strong>内部持股</strong></td>
<td><strong>收益增长</strong></td>
</tr>
<tr>
<td>Uxin (UXIN)</td>
<td>34.3%</td>
<td>74.1%</td>
</tr>
<tr>
<td>Upstart Holdings (UPST)</td>
<td>14.1%</td>
<td>57.3%</td>
</tr>
<tr>
<td>On Holding (ONON)</td>
<td>26%</td>
<td>23.1%</td>
</tr>
<tr>
<td>KVH Industries (KVHI)</td>
<td>16.3%</td>
<td>146.1%</td>
</tr>
<tr>
<td>Karman Holdings (KRMN)</td>
<td>15.6%</td>
<td>52.6%</td>
</tr>
<tr>
<td>Duos Technologies Group (DUOT)</td>
<td>11.2%</td>
<td>158.4%</td>
</tr>
<tr>
<td>Corcept Therapeutics (CORT)</td>
<td>11.7%</td>
<td>48.9%</td>
</tr>
<tr>
<td>Astera Labs (ALAB)</td>
<td>10.3%</td>
<td>29.3%</td>
</tr>
<tr>
<td>AppLovin (APP)</td>
<td>27.4%</td>
<td>21.7%</td>
</tr>
<tr>
<td>Abeona Therapeutics (ABEO)</td>
<td>16.7%</td>
<td>32.9%</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 176 stocks from our Fast Growing US Companies With High Insider Ownership screener.</p>
<div class="lb-trans"><p>点击此处查看我们高内部持股的快速成长美国公司筛选器中的 176 只股票的完整列表。</p>
</div><p>Below we spotlight a couple of our favorites from our exclusive screener.</p>
<div class="lb-trans"><p>在这里，我们重点介绍我们独家筛选器中的几只最爱。</p>
</div><h2>ImmunityBio (IBRX)</h2>
<div class="lb-trans"><h2>ImmunityBio (IBRX)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 成长评级：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> ImmunityBio, Inc. is a biotechnology company dedicated to developing and commercializing advanced immunotherapies aimed at enhancing the immune system's response to cancer and infectious diseases, with a market cap of approximately $7.25 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> ImmunityBio, Inc.是一家生物技术公司，致力于开发和商业化先进的免疫疗法，旨在增强免疫系统对癌症和传染病的反应，市值约为 72.5 亿美元。</p>
</div><p><strong>Operations:</strong> The company generates revenue of $140.98 million from its segment focused on developing next-generation therapies.</p>
<div class="lb-trans"><p><strong>运营：</strong> 该公司从其专注于开发下一代疗法的部门产生了 1.4098 亿美元的收入。</p>
</div><p><strong>Insider Ownership:</strong> 28.2%</p>
<div class="lb-trans"><p><strong>内部持股：</strong> 28.2%</p>
</div><p><strong>Earnings Growth Forecast:</strong> 64.1% p.a.</p>
<div class="lb-trans"><p><strong>收益增长预测：</strong> 每年 64.1%。</p>
</div><p>ImmunityBio, a growth-focused company with significant insider ownership, is advancing its ANKTIVA treatment for BCG-unresponsive non-muscle invasive bladder cancer. Recent FDA acceptance of its supplemental Biologics License Application could expand ANKTIVA's indications. Despite expected revenue growth of 47.8% annually, ImmunityBio faces financial challenges with less than a year of cash runway and recent shareholder dilution. Analysts agree on potential stock price appreciation, though the company currently trades significantly below estimated fair value.</p>
<div class="lb-trans"><p>ImmunityBio 是一家以增长为导向的公司，内部持股显著，正在推进其针对 BCG 无反应非肌肉侵袭性膀胱癌的 ANKTIVA 治疗。最近 FDA 接受其补充生物制剂许可证申请，可能会扩大 ANKTIVA 的适应症。尽管预计年收入增长 47.8%，ImmunityBio 面临财务挑战，现金流不足一年，且最近出现股东稀释。分析师一致认为股票价格有上涨潜力，尽管该公司目前的交易价格远低于估计的公允价值。</p>
</div><ul>
<li>Unlock comprehensive insights into our analysis of ImmunityBio stock in this growth report.</li>
<li>Upon reviewing our latest valuation report, ImmunityBio's share price might be too pessimistic.</li>
</ul>
<div class="lb-trans"><ul>
<li>解锁我们对 ImmunityBio 股票分析的全面见解，详见本成长报告。</li>
<li>在审查我们最新的估值报告后，ImmunityBio 的股价可能过于悲观。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/b2d6e0fd-dc1f-4014-8f92-60363368b53b/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/b2d6e0fd-dc1f-4014-8f92-60363368b53b/chart/earnings-and-revenue-growth"/></p>
<p>IBRX Earnings and Revenue Growth as at Jun 2026</p>
<div class="lb-trans"><p>截至 2026 年 6 月的 IBRX 收益和收入增长</p>
</div><h2>Li Auto (LI)</h2>
<div class="lb-trans"><h2>理想汽车 (LI)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 成长评级：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> Li Auto Inc. operates in the energy vehicle market in the People’s Republic of China with a market cap of approximately $14.48 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 理想汽车在中华人民共和国的能源汽车市场运营，市值约为 144.8 亿美元。</p>
</div><p><strong>Operations:</strong> Li Auto generates revenue primarily from its auto manufacturing segment, totaling CN¥109.37 billion.</p>
<div class="lb-trans"><p><strong>运营：</strong> 理想汽车主要通过其汽车制造部门产生收入，总计为 1093.7 亿人民币。</p>
</div><p><strong>Insider Ownership:</strong> 33%</p>
<div class="lb-trans"><p><strong>内部持股：</strong> 33%</p>
</div><p><strong>Earnings Growth Forecast:</strong> 61.6% p.a.</p>
<div class="lb-trans"><p><strong>收益增长预测：</strong> 每年 61.6%。</p>
</div><p>Li Auto, characterized by high insider ownership, is navigating growth amid challenges. The company forecasts a 13% annual revenue increase, outpacing the US market. However, recent earnings revealed a net loss of CNY 2.29 billion for Q1 2026 despite vehicle deliveries reaching over 1.7 million year-to-date. Li Auto's strategic moves include a US$1 billion share buyback and launching new models like the Li L9 to bolster its position in the competitive electric vehicle sector.</p>
<div class="lb-trans"><p>理想汽车以高内部持股为特征，在挑战中寻求增长。该公司预计年收入增长 13%，超过美国市场。然而，最近的收益显示 2026 年第一季度净亏损 22.9 亿人民币，尽管车辆交付量已超过 170 万辆。理想汽车的战略举措包括 10 亿美元的股票回购和推出新车型如理想 L9，以增强其在竞争激烈的电动车市场中的地位。</p>
</div><ul>
<li>Take a closer look at Li Auto's potential here in our earnings growth report.</li>
<li>Our expertly prepared valuation report Li Auto implies its share price may be too high.</li>
</ul>
<div class="lb-trans"><ul>
<li>在我们的收益增长报告中更深入地了解理想汽车的潜力。</li>
<li>我们精心准备的理想汽车估值报告表明，其股价可能过高。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/9eb69e11-e6b7-42a1-afa3-9f2354e8ac7f/chart/ownership-breakdown" alt="" original-src="https://images.simplywall.st/company/9eb69e11-e6b7-42a1-afa3-9f2354e8ac7f/chart/ownership-breakdown"/></p>
<p>LI Ownership Breakdown as at Jun 2026</p>
<div class="lb-trans"><p>截至 2026 年 6 月的 LI 持股结构</p>
</div><h2>Ethos Technologies (LIFE)</h2>
<div class="lb-trans"><h2>Ethos Technologies (LIFE)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 成长评级：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> Ethos Technologies Inc. operates as a third-party administrator for insurance policies in the United States and has a market cap of approximately $1.06 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> Ethos Technologies Inc.在美国作为保险政策的第三方管理者运营，市值约为 10.6 亿美元。</p>
</div><p><strong>Operations:</strong> The company generates revenue primarily from its insurance broker services, amounting to $485.82 million.</p>
<div class="lb-trans"><p><strong>运营：</strong> 该公司主要通过其保险经纪服务产生收入，总计为 4.8582 亿美元。</p>
</div><p><strong>Insider Ownership:</strong> 22%</p>
<div class="lb-trans"><p><strong>内部持股：</strong> 22%</p>
</div><p><strong>Earnings Growth Forecast:</strong> 94.5% p.a.</p>
<div class="lb-trans"><p><strong>收益增长预测：</strong> 每年 94.5%。</p>
</div><p>Ethos Technologies, with significant insider ownership, is expanding its digital life insurance offerings through strategic partnerships and technological advancements. Recent collaborations with Liberty Mutual and Banner Life Insurance enhance Ethos' reach and product portfolio. Despite a Q1 2026 net loss of US$166.39 million, revenue surged to US$193.1 million from the previous year. The launch of a ChatGPT app signifies their innovative approach to consumer engagement in the evolving insurance landscape, although insider selling has been noted recently.</p>
<div class="lb-trans"><p>Ethos Technologies 拥有显著的内部持股，通过战略合作和技术进步扩展其数字人寿保险产品。与 Liberty Mutual 和 Banner Life Insurance 的近期合作增强了 Ethos 的市场覆盖和产品组合。尽管 2026 年第一季度净亏损为 1.6639 亿美元，收入从去年激增至 1.931 亿美元。推出 ChatGPT 应用程序标志着他们在不断发展的保险领域中对消费者参与的创新方法，尽管最近注意到内部人士的卖出。</p>
</div><ul>
<li>Navigate through the intricacies of Ethos Technologies with our comprehensive analyst estimates report here.</li>
<li>Upon reviewing our latest valuation report, Ethos Technologies' share price might be too optimistic.</li>
</ul>
<div class="lb-trans"><ul>
<li>通过我们的全面分析师估计报告深入了解 Ethos Technologies。</li>
<li>在审查我们最新的估值报告后，Ethos Technologies 的股价可能过于乐观。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/fbc02edd-aafc-4f38-aa18-ae0098f75905/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/fbc02edd-aafc-4f38-aa18-ae0098f75905/chart/earnings-and-revenue-growth"/></p>
<p>LIFE Earnings and Revenue Growth as at Jun 2026</p>
<div class="lb-trans"><p>截至 2026 年 6 月的 LIFE 收益和收入增长</p>
</div><h2>Seize The Opportunity</h2>
<div class="lb-trans"><h2>抓住机会</h2>
</div><ul>
<li>Click this link to deep-dive into the 176 companies within our Fast Growing US Companies With High Insider Ownership screener.</li>
<li>Curious About Other Options? This technology could replace computers: discover the 30 stocks are working to make quantum computing a reality.</li>
</ul>
<div class="lb-trans"><ul>
<li>点击此链接深入了解我们高内部持股的快速成长美国公司筛选器中的 176 家公司。</li>
<li>对其他选择感到好奇？这项技术可能会取代计算机：发现 30 只股票正在努力使量子计算成为现实。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.</em></p>
<div class="lb-trans"><p><em>这篇来自 Simply Wall St 的文章是一般性的。<strong>我们提供的评论基于历史数据和分析师预测，仅使用无偏见的方法，我们的文章并不旨在提供财务建议。</strong> 它不构成买卖任何股票的推荐，也未考虑您的目标或财务状况。我们的目标是为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。该分析仅考虑内部人士直接持有的股票，不包括通过其他工具（如公司和/或信托实体）间接持有的股票。所有预测的收入和收益增长率均以年化（每年）增长率的形式表示，时间范围为 1-3 年。</em></p>
</div><h3>Valuation is complex, but we're here to simplify it.</h3>
<div class="lb-trans"><h3>估值是复杂的，但我们在这里为您简化它。</h3>
</div><p>Discover if Ethos Technologies might be undervalued or overvalued with our detailed analysis, featuring <strong>fair value estimates, potential risks, dividends, insider trades, and its financial condition.</strong></p>
<div class="lb-trans"><p>通过我们的详细分析，发现 Ethos Technologies 是否被低估或高估，分析内容包括 <strong>公允价值估算、潜在风险、股息、内部交易及其财务状况。</strong></p>
</div><p>Access Free Analysis</p>
<div class="lb-trans"><p>获取免费分析</p>
</div>

三家内部人士持股比例高的成长型公司，盈利增长可达 94%